Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash & Equivalents (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Cash & Equivalents for 17 consecutive years, with $149.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 46.09% to $149.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $149.6 million, a 46.09% increase, with the full-year FY2025 number at $149.6 million, up 46.09% from a year prior.
  • Cash & Equivalents was $149.6 million for Q4 2025 at Myriad Genetics, up from $145.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $295.2 million in Q3 2021 to a low of $53.6 million in Q1 2023.
  • A 5-year average of $123.6 million and a median of $103.5 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 149.54% in 2021, then tumbled 77.89% in 2022.
  • Myriad Genetics' Cash & Equivalents stood at $257.4 million in 2021, then crashed by 77.89% to $56.9 million in 2022, then skyrocketed by 132.16% to $132.1 million in 2023, then dropped by 22.48% to $102.4 million in 2024, then skyrocketed by 46.09% to $149.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Cash & Equivalents are $149.6 million (Q4 2025), $145.4 million (Q3 2025), and $74.4 million (Q2 2025).